Drugs / Galidesivir
Galidesivir
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03891420 | Apr 2020 → Jan 2021 | COVID-19, yellow fever | BioCryst Pharmaceuticals | Terminated | Met primary Stop: Business |
| Phase 1 | NCT03800173 | Dec 2018 → Apr 2019 | Marburg hemorrhagic fever | BioCryst Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02319772 | Dec 2014 → Mar 2016 | Ebola hemorrhagic fever | BioCryst Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2020-12-22 | BioCryst Pharmaceuticals | Results BioCryst Provides Update on Galidesivir Program biocryst.com ↗
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. |
| 2020-06-10 | BioCryst Pharmaceuticals | Results Galidesivir Stops Zika Viral Replication in Primate Model biocryst.com ↗
Galidesivir was safe and showed robust antiviral activity at all stages of Zika infection and at multiple different doses. |
| 2019-05-09 | BioCryst Pharmaceuticals | Results BioCryst Completes Phase 1 Clinical Trial of Galidesivir biocryst.com ↗
In the trial, galidesivir was generally safe and well tolerated. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference biocryst.com ↗
In the standard dose BCX4430 group, 7 of 8 mice survived through Day 28. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against Yellow Fever in a Preclinical Disease Model biocryst.com ↗
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical disease model for evaluating efficacy against yellow fever virus infection. |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection biocryst.com ↗
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced results from a proof-of-concept study of its broad spectrum antiviral BCX4430 for the treatment of experimental Ebola virus infection in rhesus macaques, conducted at the United States Army Medical Research Institute of Infectious Diseases ( USAMRIID ). |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model biocryst.com ↗ |
| 2017-10-09 | BioCryst Pharmaceuticals | Results BioCryst Announces Nature Publication Demonstrating Efficacy of BCX4430 in a Non-Human Primate Model of Filovirus Infection biocryst.com ↗
BCX4430 completely protected cynomolgus macaques from Marburg virus infection when administered by intramuscular injection 48 hours post-infection. |
All press releases naming this drug 22 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galidesivir | “Galidesivir (BCX4430) is an adenosine nucleoside analog” PMID 35182042 ↗ Feb 2022 |
| Known as | BCX4430 | “Galidesivir (BCX4430) is an adenosine nucleoside analog broadly active in cell culture against multiple RNA virus families” PMID 35182042 ↗ Feb 2022 |
| Known as | Immucillin a | ChEMBL registry synonym — accepted as the source's own label CHEMBL1236524 ↗ |
| Modality | Small molecule | “an adenosine nucleoside analog” PMID 35182042 ↗ Feb 2022 |
| Route | Intramuscular | “Administered Via Intramuscular Injection (IM)” NCT02319772 ↗ |